心臟生物植入设备的全球市场的预测:各类型，各用途，各终端用户，各国，企业分析(2024年～2032年)

全球心臟生物植入器材市场分析

全球心臟生物植入设备市场规模预计将从 2023 年的 371.3 亿美元增至 2032 年的 691.2 亿美元，2024 年至 2032 年复合年增长率为 7.15%。心臟生物植入物的兴起是由于人口老化、心血管疾病发生率相对较高、生物材料科学的进步以及全球人口越来越喜欢微创手术等因素。

心臟生物植入设备的前景

心臟生物植入装置是调节和治疗心臟容器内疾病的小型化卫生系统。此类设备包括心律调节器、除颤器、生物假体心臟瓣膜和心室辅助装置 (VAD)。心律调节器透过使用可以控制心跳的电讯号来帮助控制不规则的心跳。另一方面，当发现医学上严重的心律不整时，除颤器用于对心臟进行电击。机械心臟瓣膜是合成瓣膜，可取代有缺陷或患病的天然瓣膜，并保持血液以正确的方式流经心臟。心室辅助装置透过补充心臟的泵血功能来帮助患有严重心臟衰竭的患者，特别是等待心臟移植的患者。

这些心臟生物植入装置透过填补心臟组织的间隙来改善心臟病患者的生活品质。因此，它可以缓解症状，改善心臟功能，并减少致命事件的机会。心律调节器和除颤器用于帮助您实现适当的节律并避免中风或心臟衰竭等明显问题。生物人工心臟瓣膜可增加体内血液循环，减轻心臟负担。心室辅助装置为末期心臟衰竭患者提供所需的支持，增加他们在等待心臟移植期间的生存机会和整体健康状况。新技术的发展正在为全球数千万患者带来光明和美好前景。

推动心臟生物植入设备市场的因素

世界各地的老化

全球人口老化是心臟生物植入物市场的主要成长因素之一。心血管疾病包括心臟衰竭、心律不整和心臟瓣膜疾病，其发生率随着年龄的增长而增加。 65 岁以上的患者更容易罹患各种需要侵入性手术的心臟疾病，例如心律调节器、除颤器，甚至瓣膜。因此，老年人口数量不断增加，对这些维持生命的发明的需求不断增加，市场不断扩大。此外，医疗领域的新技术创新和更好的健康结构使得向老龄化人口的关键部分供应这些设备成为可能，从而推动了市场的发展。

技术进步

随着医疗领域新技术的引入，心臟生物植入市场正在不断发展。无引线心律调节器、MRI 相容设备和微创手术等新技术正在提高这些植入物的安全性和性能，并提高患者的舒适度。具有远端监控功能的便携式设备可以持续评估患者状况并及时进行干预，以防止住院和不良结果。此外，生物材料合成和组织工程技术的进步有助于提高现有生物人工心臟瓣膜的强度和性能并扩大其用途。这些技术进步正在成为市场驱动力，因为它们提供了更好的治疗设施并扩大了心臟生物植入物的使用。

心血管疾病盛行率增加

心血管疾病盛行率的上升是整个心臟生物植入物市场的主要成长动力。世界各地的心臟病病例不断增加，因为许多人吃不健康的食物、很少运动、久坐的生活方式、体重超重和感到压力。随着越来越多的患者被诊断出心臟衰竭、心律不整和 CAD 等疾病，对心臟生物植入物来解决这些问题的需求也在增加。供应商还指出，政府和卫生部门正在推动提高认识活动和早期诊断计划，以增加识别心臟病患者的可能性，这可能会促使用于治疗疾病的植入设备的出现，这有助于扩大对设备的需求。

本报告研究了全球心臟生物植入设备市场，并提供了市场成长驱动因素和课题、市场占有率以及主要参与者的分析。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

• 成长促进因素
• 课题

第5章 心臟生物植入设备市场

第6章 市场占有率

• 各类型
• 各用途
• 各终端用户
• 各国

第7章 类型

• 心律调节器
• ICD(植入式心臟整流去颤器)
• CRT(心臟再同步化治疗)

第8章 用途

• 心律不整
• 心肌缺血
• 急性心肌梗塞
• 心臟衰竭

第9章 终端用户

• 医院
• 门诊病人手术中心
• 心导管检验室
• 其他

第10章 国家

• 北美
  • 美国
  • 加拿大
• 欧洲
  • 法国
  • 德国
  • 义大利
  • 西班牙
  • 英国
  • 比利时
  • 荷兰
  • 瑞士
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 泰国
  • 马来西亚
  • 印尼
  • 菲律宾
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东·非洲
  • 南非
  • 沙乌地阿拉伯
  • 土耳其
  • 阿拉伯联合大公国
• 其他地区

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企业的分析

• F. Hoffman-La Roche
• Eurofins Scientific
• Illumina, Inc.
• Natera Inc.
• Abbott Laboratories
• Thermo Fisher Scientific
• Quest Diagnostics
• Agilent Technologies

Global Cardiac Bio Implant Devices Market Analysis

The market for the Cardiac Bio Implant Devices will be US$ 69.12 billion by 2032 from US$ 37.13 billion in 2023 with a Compound Annual Growth Rate of 7.15% between 2024 and 2032. Cardiac bioimplant arises from causes-such as the aging population, relatively higher incidences of cardiovascular diseases, developments in biomaterial science and an ever-rising global population with a penchant for procedures that do not require much intrusion.

Cardiac Bio Implant Devices Outlooks

Cardiac bioimplant devices are miniaturized health systems that regulate and cure disease of the heart containers. Such devices include pacemakers, defibrillators, bio-prosthetic heart valves as well as ventricular assist devices (VADs). Pacemakers therefore assist in controlling irregular heartbeats using electrical signals that are capable of controlling the heartbeat. In turn, defibrillators are used to apply electrical shocks to the heart if it identifies medically serious forms of the arrhythmia. Mechanical heart valves are synthetic and replace the natural ones that are either faulty or have a disease, and keep the blood flowing in the right way through the heart VADs assist patients with severe heart failure help by supplementing the pumping function of the heart especially to those awaiting on heart transplants.

These cardiac bio-implant devices improve the quality of life of patients with cardiac issues by filling the gap in heart tissue. It therefore relieves symptoms, enhances the function of the heart, and decreases the probability of fatal occurrences. Pacemakers and defibrillators are used to approach a proper rhythm and avoid such conspicuous issues as stroke or failure of the heart. Bio-prosthetic heart valves enhance the circulation of blood in the body meaning less workload to the heart. VADs offer much-needed support to the patients with end stage heart failure, boosting the patients' survival rates and general well-being while waiting for the heart transplant. New technological development gives a silver lining and better prospects for tens of millions of patients globally.

Driving Forces for Cardiac Bio Implant Devices Market

Aging population worldwide

The global ageing population is one of the main growth stimulants for the cardiac bio implant devices market. Cardiovascular diseases include heart failure, arrhythmias, and valvular heart diseases, and their occurrence raises with age. Patients above 65 years are prone to suffer different heart diseases that need invasive procedures like pacemakers, defibrillators, and even valves. This has ensured that there is an increase in the number of elderly people, and hence the need for these lives supporting inventions hence increasing the market. Also, new innovations in the medical field and better health structures make the delivery of these devices to a crucial demographic of the aging population feasible, thereby boosting its market.

Technological Advancements

The market for Cardiac bio-implant devices is advancing due to the introduction of the latest technology in the medical field. New technologies including leadless pacemakers, MRI compatible devices, and Minimal invasive surgery these have enhanced the safety and performance of these implants and also the comfort of the patients. The portable devices with remote monitoring permits a constant assessment of the conditions of the patients and their timely intervention to prevent hospitalizations and worsened results. Also, technological improvements in the synthesis of the biomaterials and tissue engineering helped in improving the strength and performance of existing bio-prosthetic heart valves hence extending their use. These are the technological advancements that are acting as the driving force for the market as it provides better treatment facilities and has expanded the usage of cardiac bio-implants.

Rising Incidence of Cardiovascular Diseases

Rising incidence of cardiovascular diseases is a key factor that will foster the growth of the overall market for cardiac bio implant devices. Most people consume unhealthy foods, hardly exercise, lead a sedentary life, are overweight and stressed which are leading them to increased cases of heart diseases globally. As a large number of the patients are diagnosed with diseases like heart failure, arrhythmia, or CAD, the need for troubled solutions, cardiac bio-implants, increases as well. Suppliers also find governments and healthcare sectors promoting awareness campaigns and early diagnosis programs so as to increase the chances of identifying patients with the cardiac diseases, contributing to the enhanced requirement for the implantable devices to manage the diseases.

Favourable Reimbursement Policies

The reimbursement policies in particular and the insurance coverage of the cardiac bio-implant procedures are key factors that have huge impacts on the growth of the market. Different developed countries have health insurance schemes and government healthcare programs that cater for a number of costs pertaining to cardiac implants. It assists in alleviating the costs of treatment and extends the possibility of great-quality cardiac treatment to more people. Also, prices have been influenced by the shift in health care reforms and outcomes-based care which include the use of high quality cardiac implant devices. It is these employment policies and financial incentive that contributes to the market by ensuring these invaluable pieces of equipment's are easily within reach.

Asia Pacific Cardiac Bio Implant Devices Market

With the increased rate of cardiovascular disease, increasing population, and higher health care expenses, the Asia Pacific cardiac bio implant devices market is progressing at a higher rate. Administrations of countries such as China, India, and Japan are major players in opening up the market due to the advancement of healthcare facilities and increased awareness of cardiac diseases. Some of these drivers include; technological progress and development such as minimally invasive surgeries and improved bio-prosthetic heart valves. More so, the availably of the devices is boosting through friendly government policies and take up of insurance products. This market is further augmented by the rising focus on the early screening and prevention that enhance the sales of pacemakers, defibrillators, and other cardio devices in the region.

Cardiac Bio Implant Devices Company Analysis

The top companies in the Cardiac Bio Implant Device industry are F. Hoffman-La Roche, Eurofins Scientific, Illumina, Inc., Natera, Inc., Abbott Laboratories, Thermo Fisher Scientific, Quest Diagnostics, and Agilent Technologies.

Cardiac Bio Implant Devices Company News

Roche signed a $2.7 billion cash deal in December 2023 to acquire US-based Carmot Therapeutics.

In February 2021, Medtronic introduced the TYRX Absorbable Antibacterial Envelope. This unique, one-time-use envelope has antimicrobial qualities and supports implanted neurostimulators or cardiac implantable electrical devices.

Type- Market breakup in 3 viewpoints:

1. Pacemaker

2. ICDs

3. CRT

Application- Market breakup in 4 viewpoints:

1. Arrhythmias

2. Myocardial Ischemia

3. Acute Myocardial Infarction

4. Heart Failure

End User- Market breakup in 4 viewpoints:

1. Hospitals

2. Ambulatory Surgical Centers

3. Cardiac Catheterization Laboratories

4. Others

Country - Market breakup of 25 Countries:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherland
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

6. Rest of the world

All the key players have been covered from 4 Viewpoints:

• Business Overview
• Product Portfolio
• Recent Development & Strategies
• Revenue Analysis

Key Players Analysis:

1. F. Hoffman-La Roche

2. Eurofins Scientific

3. Illumina, Inc.

4. Natera Inc.

5. Abbott Laboratories

6. Thermo Fisher Scientific

7. Quest Diagnostics

8. Agilent Technologies

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Cardiac Bio Implant Devices Market

6. Market Share

• 6.1 By Type
• 6.2 By Application
• 6.3 By End User
• 6.4 By Countries

7. Type

• 7.1 Pacemaker
• 7.2 ICDs (Implantable Cardioverter Defibrillator)
• 7.3 CRT (Cardiac Resynchronization Therapy)

8. Application

• 8.1 Arrhythmias
• 8.2 Myocardial Ischemia
• 8.3 Acute Myocardial Infarction
• 8.4 Heart Failure

9. End-User

• 9.1 Hospitals
• 9.2 Ambulatory Surgical Centers
• 9.3 Cardiac Catheterization Laboratories
• 9.4 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherlands
  • 10.2.8 Switzerland
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 Australia
  • 10.3.5 South Korea
  • 10.3.6 Thailand
  • 10.3.7 Malaysia
  • 10.3.8 Indonesia
  • 10.3.9 Philippines
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 MEA
  • 10.5.1 South Africa
  • 10.5.2 Saudi Arabia
  • 10.5.3 Turkey
  • 10.5.4 UAE
• 10.6 Rest of the World

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 F. Hoffman-La Roche
  • 13.1.1 Overview
  • 13.1.2 Product Portfolio
  • 13.1.3 Recent Development
  • 13.1.4 Revenue Analysis
• 13.2 Eurofins Scientific
  • 13.2.1 Overview
  • 13.2.2 Product Portfolio
  • 13.2.3 Recent Development
  • 13.2.4 Revenue Analysis
• 13.3 Illumina, Inc.
  • 13.3.1 Overview
  • 13.3.2 Product Portfolio
  • 13.3.3 Recent Development
  • 13.3.4 Revenue Analysis
• 13.4 Natera Inc.
  • 13.4.1 Overview
  • 13.4.2 Product Portfolio
  • 13.4.3 Recent Development
  • 13.4.4 Revenue Analysis
• 13.5 Abbott Laboratories
  • 13.5.1 Overview
  • 13.5.2 Product Portfolio
  • 13.5.3 Recent Development
  • 13.5.4 Revenue Analysis
• 13.6 Thermo Fisher Scientific
  • 13.6.1 Overview
  • 13.6.2 Product Portfolio
  • 13.6.3 Recent Development
  • 13.6.4 Revenue Analysis
• 13.7 Quest Diagnostics
  • 13.7.1 Overview
  • 13.7.2 Product Portfolio
  • 13.7.3 Recent Development
  • 13.7.4 Revenue Analysis
• 13.8 Agilent Technologies
  • 13.8.1 Overview
  • 13.8.2 Product Portfolio
  • 13.8.3 Recent Development
  • 13.8.4 Revenue Analysis